CONMED Appoints Two Highly Experienced MedTech Executives to Board

summarizeSummary

CONMED appointed two highly experienced independent directors from Johnson & Johnson and Boston Scientific, strengthening its board with deep MedTech expertise, and named an internal candidate as Interim Principal Accounting Officer.

check_boxKey Events

• Board Expansion & New Directors Appointed

  The Board of Directors increased to nine members with the appointment of Celine Martin (ex-J&J MedTech) and Jeff Mirviss (ex-Boston Scientific) as independent directors, effective July 1, 2026.

• Enhanced Governance & Strategic Expertise

  Ms. Martin will join the Audit and Strategy Committees, while Mr. Mirviss will join the Compensation and Corporate Governance and Nominating Committees, bringing over 30 years of healthcare industry leadership each.

• Interim Principal Accounting Officer Appointed

  Kimberly Lockwood, a long-term employee and CPA, was appointed Interim Corporate Controller and Interim Principal Accounting Officer, effective June 1, 2026, providing continuity in the role following a previous interim departure.

• Bylaw Amendments Adopted

  The company adopted amended and restated by-laws to reflect current Delaware law and market practices, including updates to advance notice provisions for stockholder nominations and requiring director candidates to be available for interviews.

auto_awesomeAnalysis

CONMED has significantly strengthened its board by appointing Celine Martin (ex-J&J MedTech) and Jeff Mirviss (ex-Boston Scientific) as independent directors. Their extensive industry experience, particularly in high-growth medical technology and global business leadership, is expected to enhance strategic oversight and support the company's long-term growth initiatives. The board size has been increased to accommodate these additions, and they will serve on key committees. Additionally, the company appointed an internal candidate as Interim Principal Accounting Officer, ensuring continuity in a key financial role.